Investment Thesis
Ceribell exhibits classic pre-profitability medical device company characteristics: strong 36% revenue growth and exceptional 87% gross margins demonstrate product-market fit and pricing power, but severe operating losses (-78% margin) and negative cash burn (-$19.3M annually) signal company is far from profitability. With $45.3M cash and no debt, runway exists for 2+ years, making execution on cost control and revenue scaling the determining factor for viability.
Strengths
- Strong 36.1% YoY revenue growth demonstrates market traction
- Exceptional 87.3% gross margin indicates healthy unit economics and pricing power
- Fortress balance sheet: $45.3M cash, zero debt, 10.4x current ratio provides multi-year runway
- Improving EPS (56.9% YoY) signals operating leverage improving despite losses
Risks
- Severe cash burn: -$19.3M operating cash flow against $26.5M revenue is unsustainable long-term
- Deep unprofitability: -78.3% operating margin and -74.5% net margin after reaching $26.5M scale suggests structural cost issues
- Negative free cash flow of -$19.4M means growth is funded by balance sheet depletion, not cash generation
- Medical device sector requires sustained R&D spend and regulatory compliance; gross margin compression or revenue slowdown would be critical
Key Metrics to Watch
- Operating cash flow trajectory: must turn positive before cash reserves deplete
- Operating margin expansion: must show path to breakeven as revenue scales
- Cash runway: current $45.3M with -$19.3M burn rate critical; monitor quarterly burn rate
- Revenue growth sustainability: confirm 36% growth is not demand front-loading; monitor cohort retention
Financial Metrics
Revenue
26.5M
Net Income
-19.7M
EPS (Diluted)
$-0.52
Free Cash Flow
-19.4M
Total Assets
178.1M
Cash
45.3M
Profitability Ratios
Gross Margin
87.3%
Operating Margin
-78.3%
Net Margin
-74.5%
ROE
-14.0%
ROA
-11.1%
FCF Margin
-73.3%
Balance Sheet & Liquidity
Current Ratio
10.44x
Quick Ratio
10.01x
Debt/Equity
0.00x
Debt/Assets
20.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:03:44.143183 |
Data as of: 2026-03-31 |
Powered by Claude AI